Glenmark to Conduct Trial of Favipiravir as COVID-19 Treatment

Mumbai-based Glenmark Pharmaceuticals received approval for a clinical trial in India of its antiviral favipiravir as a potential COVID-19 treatment.

The initial 28-day trial will assess the influenza drug in 150 subjects with mild-to-moderate COVID-19 infections, randomized to receive either favipiravir or standard care.

Glenmark is the first drugmaker in India approved to test a potential COVID-19 treatment.